The Amsterdam-based European Union regulator said the antiviral pill, known as molnupiravir, can be used to treat adults infected with theThe agency said in a statement the drug should be given as soon as possible after
The most common side effects reported during treatment and within 14 days after the last dose of molnupiravir were diarrhea, nausea, dizziness and headache, all of which were either mild or moderate. The US Food and Drug Administration announced last month it would convene a panel of independent experts to scrutinise the pill’s safety and effectiveness in late November.Merck has said it can produce 10 million treatment courses through the end of the year, but much of that supply has already been purchased by governments worldwide.The European Union's drug regulator said it has started evaluating the COVID-19 pill made by Pfizer Inc.
Early results suggest Pfizer's pill reduces the risk of hospitalisation or death, compared with people who received a dummy pill, when they were treated within three to five days of developing COVID-19 symptoms, the agency said.